User:Mr. Ibrahem/Valbenazine

Mr. Ibrahem/Valbenazine
Clinical data
Trade names	Ingrezza
Other names	NBI-98854
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
Drug class	Vesicular monoamine transporter 2 inhibitor (VMAT2)
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	>99%
Metabolism	Activation by hydrolysis, deactivation by CYP3A, CYP2D6
Metabolites	[+]-α-Dihydrotetrabenazine (active metabolite)
Elimination half-life	15–22 hrs
Excretion	60% urine, 30% faeces
Identifiers
	IUPAC name (2R,3R,11bR)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl L-valinate;
Chemical and physical data
Formula	C24H38N2O4
Molar mass	418.578 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C[C@@H]1CN2CCc3cc(c(cc3[C@H]2C[C@H]1OC(=O)[C@H](C(C)C)N)OC)OC;
	InChI InChI=InChI=1S/C24H38N2O4/c1-14(2)9-17-13-26-8-7-16-10-21(28-5)22(29-6)11-18(16)19(26)12-20(17)30-24(27)23(25)15(3)4/h10-11,14-15,17,19-20,23H,7-9,12-13,25H2,1-6H3/t17-,19-,20-,23+/m1/s1 ; Key:GEJDGVNQKABXKG-CFKGEZKQSA-N ;

Valbenazine, sold under the trade name Ingrezza, is a medication used to treat tardive dyskinesia, a long term movement disorder due to antipsychotics.^[1] It is taken by mouth.^[1] Long term use is required.^[1]

Common side effects include dry mouth, sleepiness, urinary retention, dizziness, and headache.^[1] Other side effects include QT prolongation.^[2] Use is not recommended in those with severe kidney problems.^[1] It is a vesicular monoamine transporter 2 (VMAT2) inhibitor.^[1]

Valbenazine was approved for medical use in the United States in 2017.^[1] As of 2018 it costs 5,750 to 6,225 USD per month.^[2] It is only available at certain pharmacies.^[3] There is not currently plans to sell it in Europe as of 2018.^[4]

References[edit]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Valbenazine Monograph for Professionals". Drugs.com. Archived from the original on 24 January 2021. Retrieved 4 August 2021.
^ ^a ^b Uhlyar, S; Rey, JA (June 2018). "Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia". P & T : a peer-reviewed journal for formulary management. 43 (6): 328–331. PMID 29896031.
^ "Ingrezza Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 21 April 2019. Retrieved 5 August 2021.
^ "Valbenazine". SPS - Specialist Pharmacy Service. Archived from the original on 27 August 2021. Retrieved 6 August 2021.

[AHFS2021-1] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Valbenazine Monograph for Professionals". Drugs.com. Archived from the original on 24 January 2021. Retrieved 4 August 2021.

[Uh2018-2] Uhlyar, S; Rey, JA (June 2018). "Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia". P & T : a peer-reviewed journal for formulary management. 43 (6): 328–331. PMID 29896031.

[GX2021-3] "Ingrezza Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 21 April 2019. Retrieved 5 August 2021.

[SPS2021-4] "Valbenazine". SPS - Specialist Pharmacy Service. Archived from the original on 27 August 2021. Retrieved 6 August 2021.

[1]

[2]

[3]

[4]